The Primary Care Diabetes Society
Now Virtual
Organised by the PCDS, the only association solely committed to the needs of primary care diabetes, this virtual conference will examine diabetes care from a Scottish perspective. This year, the 13th for the event, we will celebrate the heritage of this event by doing what we do best: exploring a range of issues that impact the most on day-to-day diabetes care delivery in Scotland. And we will be doing so in a new virtual format.
As the Scottish representatives of the PCDS Committee, we are delighted to be delivering this invaluable opportunity for us all to come together, virtually, and discuss the real core issues in Scottish diabetes care delivery.
We look forward to welcoming you to the virtual conference.
Kevin Fernando, GP, North Berwick
Paul Newman, GP, Glasgow
Why attend? This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more
Ask the experts your burning questions through the LIVE Q&A at the end of each session
Log on anytime during the day from the comfort of your own home to view the sessions
Don’t worry if you miss something, all of the content will be available on-demand
Claim 5 CPD points for the full day virtual conference
09.00 - 09.10
Chair’s introduction
Kevin Fernando
09.10 - 09.40
Diabetes & physical activity: Is sitting the new smoking?
- Review of the evidence on the impact of sedentary habits
- Some simple tips people can use to break the habits
Jason Gill
15 minute break
Symposia
09.55 - 10.25
CREDENCE Trial – A New Era in the Treatment of Diabetic Kidney Disease (DKD) in Type 2 Diabetes Mellitus (T2DM)
- This promotional symposium has been organised and funded for by Napp Pharmaceuticals Ltd
Chris Smith & Lyndsey McConnell
15 minute break
10.40 - 11.10
Complications of diabetes: The unknown unknowns
- What are the key complications?
- How we can be vigilant to the early signs
- How management can keep the risk at bay
Kevin Fernando
15 minute break
11.25 - 12.05
‘In Practice’ masterclasses
Rotation 1
1. Hitting a nerve: Neuropathy in diabetes
- How to spot the development of neuropathy
- What can be done to slow and manage this complication?
Paul Newman
2. Deconstructing dietetic advice
- What does a ‘good diet’ really look like, and for whom?
- How we can help with adherence to advice
Jessica Fletcher
3. What after metformin?
- A review of the current options
- How we can decide between the options for different patients
Nicola Milne
4. ‘In association’ masterclass
15 minute break
12.20 - 13.00
Rotation 2
1. Hitting a nerve: Neuropathy in diabetes
- How to spot the development of neuropathy
- What can be done to slow and manage this complication?
Paul Newman
2. Deconstructing dietetic advice
- What does a ‘good diet’ really look like, and for whom?
- How we can help with adherence to advice
Jessica Fletcher
3. What after metformin?
- A review of the current options
- How we can decide between the options for different patients
Nicola Milne
15 minute break
13.15 - 13.45
Severe mental health and diabetes
- How poor mental health impacts on the management of diabetes
- How to spot the ‘warning signs’
- What we can do to help
Zoe Sherwood
15 minute break
14.00 - 14.30
Symposia
15 minute break
14.45 - 15.15
Diabetes distilled
- Emerging evidence from the weeks and months before the conference
Pam Brown
15.15 - 15.25
Chair’s concluding remarks
Kevin Fernando
A full-day virtual conference
20 October 2020 from 9am
Including a LIVE Q&A after every session
Speakers
Pam Brown
Kevin Fernando
Jessica Fletcher
Diabetes Specialist Dietitian, NHS Highland, Argyll and Bute HSCP
Jason Gill
Professor of Cardiometabolic Health, Institute of Cardiovascular and Medical Sciences, University of Glasgow
Lyndsey McConnell
Nicola Milne
Community Diabetes Specialist Nurse, Manchester University Foundation Trust
Paul Newman
Zoe Sherwood
Inpatient Diabetes Specialist Nurse, Birmingham & Solihull Mental Health Foundation Trust (BSMHFT)
Chris Smith
Lyndsey McConnell
Nicola Milne
Community Diabetes Specialist Nurse, Manchester University Foundation Trust
Paul Newman
Sponsors
Kevin Fernando
Jason Gill
Paul Newman
Jessica Fletcher
Diabetes Specialist Dietitian, NHS Highland, Argyll and Bute HSCP
Conference
Sponsors
GOLD SPONSOR
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit www.astrazeneca.co.uk
SILVER SPONSOR
Napp Pharmaceuticals Limited
Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. We strive to offer new medicines and initiatives that support the NHS in delivering effective, high-quality, sustainable healthcare for the benefit of patients
Masterclass sponsor
Abbott’s Diabetes Care Division
Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk
BRONZE SPONSORS
Boehringer Ingelheim and Lilly Diabetes Alliance
AgaMatrix
AgaMatrix manufactures and supplies WaveSense JAZZ™ blood glucose meters, diabetes data management solutions and provides services and support to help you reduce the cost of diabetes care.
With uncompromising accuracy as our cornerstone, we strive to ensure the highest quality diabetes monitoring products and services are supplied at the lowest possible cost.
Find out about our innovative new device, JAZZ™ DoseCoach, the UK’s first evidence-based basal insulin only advisor with built-in blood glucose meter. The device helps patients with type 2 diabetes optimise their once daily insulin glargine dose and is proven to reduce HbA1c.
Boehringer Ingelheim in the UK
We are Boehringer Ingelheim – a different kind of pharmaceutical company. Family-owned. Purpose-led. Innovation-driven: We serve mankind by improving health for people and animals.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Established in 1885, we have always been independent and family-owned, meaning we have the freedom to pursue our purpose – identifying health challenges of the future, and targeting areas of need where we can do the most good.
By working collaboratively, we accelerate the delivery of medical breakthroughs to transform the lives of patients now, and for generations to come.
In the UK we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. We support digital transformation by partnering with innovators to drive healthcare improvements.
We are committed to tackling the challenge of climate change and are a certified carbon neutral organisation. We serve local and global communities through our social impact programme and we support social entrepreneurs who find healthcare solutions for the most vulnerable.
More information can be found at www.boehringer-ingelheim.co.uk
PC-GB-102424 – Date of Preparation August 2020
Eli Lilly and Company Ltd
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.co.uk
Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.
In the UK, where some of medicines have been helping patients for more than 50 years, we have a portfolio of over 500 products that include branded, generic, over the counter, antiretroviral and biosimilar medicines. Learn more at www.mylan.co.uk.
Novo Nordisk
At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.
Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.
For more information visit novonordisk.co.uk
